CD23+IgG1+ memory B cells are poised to switch to pathogenic IgE production in food allergy

Food allergy is caused by allergen-specific immunoglobulin E (IgE) antibodies, but little is known about the B cell memory of persistent IgE responses. Here, we describe, in human pediatric peanut allergy, a population of CD23+IgG1+ memory B cells arising in type 2 immune responses that contain high-affinity peanut-specific clones and generate IgE-producing cells upon activation. The […]

Advancements in peanut mechanization: Implications for sustainable agriculture

Context: Peanuts (Arachis hypogaea) hold significant global economic and nutritional importance, positioning them as a crucial crop in the realm of sustainable agriculture. In this comprehensive systematic and meta-analytic review, we thoroughly examine the extensive research and innovative strategies related to mechanizing peanut farming, with a specific focus on activities encompassing tilling, sowing, and harvesting. […]

Maize/peanut rotation intercropping improves ecosystem carbon budget and economic benefits in the dry farming regions of China

Monoculture is widely practiced to increase crop productivity, but long-term adaptation has drawbacks as it increases the depletion of soil nutrients and reduces soil quality, especially in dryland areas. Conversion from traditional maize monoculture to intercropping improves sustainable production. However, maize/peanut intercropping, especially rotation of planting strips impacts of maize/peanut intercropping in dryland on carbon […]

Pediatric oral food challenges in the outpatient setting: A single-center experience

Background: Oral food challenge (OFC) is the criterion standard for diagnosing food allergy (FA). It is important to have parameters to aid in selecting ideal OFC candidates. Objective: We sought to characterize outcomes and predictors of OFCs for common food allergens. Methods: We completed a retrospective chart review of all OFCs for IgE-mediated FA performed […]

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy

Background: Food allergy is a leading cause of anaphylaxis worldwide. Allergen-specific immunotherapy is the only treatment shown to modify the natural history of allergic disease, but application to food allergy has been hindered by risk of severe allergic reactions and short-lived efficacy. Allergen-derived peptides could provide a solution. PVX108 comprises seven short peptides representing immunodominant […]

Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial

Background: Prior studies of peanut sublingual immunotherapy (SLIT) have suggested a potential advantage with younger age at treatment initiation. Objective: We studied the safety and efficacy of SLIT for peanut allergy in 1- to 4-year-old children. Methods: Peanut-allergic 1- to 4-year-old children were randomized to receive 4 mg peanut SLIT versus placebo. Desensitization was assessed […]

A Randomized, Placebo-Controlled Phase 1 Safety Study of OMIT in Adults with Peanut Allergy

Introduction: Oral Mucosal Immunotherapy (OMIT) uses a specially formulated toothpaste to deliver allergenic proteins to immunologically active areas of the oral cavity, a delivery mechanism which has the greatest potential for food allergy desensitization. OMIT presents advantages over other approaches to allergy immunotherapy due to its targeted delivery and simplified administration, supporting the goal of […]

Fast impedimetric immunosensing of IgGs associated with peanut and hazelnut allergens

Food allergies trigger a variety of clinical adverse symptoms and clinical evidence suggests that the presence of food allergy-related IgG can be helpful in the diagnosis when analyzed at the peptide-epitope level. To validate and select the peptides based on their specificity toward hazelnut or peanut epitopes, the authors of this study developed a silicon-based […]

Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial

Background: Prior studies of peanut sublingual immunotherapy (SLIT) have suggested a potential advantage with younger age at treatment initiation. Objective: We studied the safety and efficacy of SLIT for peanut allergy in 1- to 4-year-old children. Methods: Peanut-allergic 1- to 4-year-old children were randomized to receive 4 mg peanut SLIT versus placebo. Desensitization was assessed […]